This Hepatitis Stock Has 'Multiple Paths To Value Creation,' Expects To Double, Bullish Analyst Predicts

SVB Leerink initiated coverage on Vir Biotechnology Inc VIR with an Outperform rating and a price target of $40, with an investment thesis based on:
With multiple clinic programs, Vir is well-positioned as a leading infectious disease & commercial-stage biopharma company.
Vir developed and globally distributed its first generation COVID-19 antiviral, sotrovimab (Xevudy), and received repeat US government contracts.
Xevudy generated around $2.6 billion in revenues that could provide robust funds to support Vir’s multiple clinical development efforts without the need for any near-term capital.
Vir is developing next-gen COVID-19 antibodies like VIR-7832 with potentially greater potency and broader coverage against new COVID-19 variants. The analyst forecasts peak non-risk adjusted sales of ~$360 million in 2026E for VIR-7832.
Different combinations of Vir’s HBV assets and forecasts peak non-risk adjusted HBV sales of ~$2.8 billion in 2031E for Vir’s potential final HBV combination regimen.
Additional data could validate Vir’s early-stage influenza and HIV programs.
Also Read: Vir Biotech Shuns FDA Submission Plans For GSK-Partnered COVID-19 Treatment.
Price Action: VIR shares are up 2.87% at $21.16 on the last check Wednesday.

Momentum12.12

GrowthNot Available

QualityNot Available

Value9.71

Short

Medium

Long

Analyst Calendar